Fluidda, Materialise Expand Partnership to Develop Personalized Solutions for Lung Patients
LEUVEN, Belgium, May 10, 2019 – Fluidda announces a new phase in its collaboration with Materialise (NASDAQ: MTLS), to expand personalized treatment options in respiratory care, building on its image-based software. As part of the partnership, Materialise invests €2.5 million in Fluidda and Wilfried Vancraen, founder and CEO of Materialise, will join the board of directors at Fluidda.
The companies want to collaborate more closely to accelerate the development of personalized solutions in pulmonology. Fluidda’s proprietary imaging technology, Functional Respiratory Imaging (FRI) based on airflow monitoring, combines CT scan images with computer-based flow simulations, allowing for better visualization of airflows in lung patients. By combining this with the experience of Materialise in medical 3D printing and planning, both companies want to develop more personalized solutions that can help the growing number of patients suffering from COPD, asthma, and other respiratory diseases.
As part of the partnership, Materialise led a 4mio EUR funding round with a 2.5mio EUR investment. Fluidda will use part of these resources to accelerate this joint development of a treatment solution that can support clinicians to help patients with a personalized regional treatment, based upon the FRI technology.
Wilfried Vancraen, founder and CEO of Materialise, will join the board of directors at Fluidda. He brings 30 years of experience as an entrepreneur in 3D printing and personalized approaches in the medical field.
“We are very excited and proud to enter into this new phase of partnership with Materialise. We share the vision that the medical field and particularly respiratory healthcare imaging needs to evolve towards personalized, precision medicine through a value-based healthcare approach. We are confident that advanced imaging techniques, such as our Functional Respiratory Imaging methods, can add value in this regard.” Jan De Backer, CEO of Fluidda
Wilfried Vancraen, CEO of Materialise, states: “Fluidda was one of the first users of the pulmonology features of the Materialise Mimics software suite and it is a nice example of how new technologies for healthcare diagnostics are being developed in collaboration with Materialise’s expertise in medical engineering. With this partnership we can help even more patients, bringing the possibilities of 3D printing and planning to the pulmonology market.”
Materialise incorporates 27 years of 3D printing experience into a range of software solutions and 3D printing services, which together form the backbone of the 3D printing industry. Materialise’s open and flexible solutions enable players in a wide variety of industries, including healthcare, automotive, aerospace, art and design, and consumer goods, to build innovative 3D printing applications that aim to make the world a better and healthier place. Headquartered in Belgium, with branches worldwide, Materialise combines the largest group of software developers in the industry with one of the largest 3D printing facilities in the world. For additional information, visit www.materialise.com.
About Materialise’s Medical Division
Materialise Medical, which has pioneered many of the leading medical applications of 3D printing, enables researchers, engineers and clinicians to revolutionize innovative patient-specific treatment that helps improve and save lives. Materialise Medical’s open and flexible platform of software and services, Materialise Mimics, forms the foundation of certified Medical 3D printing, in clinical as well as research environments, offering virtual planning software tools, 3D-printed anatomical models, and patient-specific surgical guides and implants. For additional information, please visit: www.materialise.com/medical.
Fluidda, a world-leading Lung Imaging Company, headquartered in Belgium, uses artificial intelligence and advanced machine learning to combine low dose High-Resolution CT Scan images with advanced computer-based flow simulations (Computational Fluid Dynamics), allowing for better care of lung patients. Fluidda’s proprietary technology, Functional Respiratory Imaging (FRI), has been used in more than 80 clinical studies over the last 10 years, supporting the Respiratory Health Community and Clinical Research to enhance drug development and patient care. For more information, visit www.fluidda.com.